Theratechnologies Q3 Earnings Lags Consensus As Trogarzo Sales Decline

  • Theratechnologies Inc THTX reported Q3 sales of $17.85 million, +27% Y/Y propelled by higher Egrifta sales of $11.22 million, +64%. The revenue missed the consensus of $19.66 million.
  • Trogarzo sales declined 8% to $6.63 million on lower unit sales as patients refrained from visiting their physicians. Competitive pressures and higher rebates also impacted the sales.
  • It posted a net loss of $(0.10) for the quarter compared to $(0.09) a year ago, missing the consensus loss of $(0.07).
  • The Company used $(3.13) million in operating cash flow.
  • Price Action: THTX shares closed lower by 0.14% at $3.50 on Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsPenny StocksSmall CapTechBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!